XORTX Therapeutics (XRTX) Stock Price, News & Analysis

Company Overview

XORTX Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing therapies for diseases associated with abnormal uric acid metabolism and kidney dysfunction. The company’s research centers on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of reducing kidney injury and slowing disease progression.

XORTX’s lead development program, XRx-008, is being investigated as a potential treatment for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function. The company has also described additional programs involving its uric acid-lowering platform for acute kidney injury and other conditions linked to kidney disease and metabolic dysfunction.

Based in Calgary, Alberta, Canada, XORTX serves the global pharmaceutical and biotechnology market through drug development activities and collaborations. The company’s programs remain in clinical development, and its product candidates have not necessarily received regulatory approval for commercial sale.

Key Stats

• Today's Range: $1.39 to $1.90
• 50-Day Range: $1.41 to $2.48
• 52-Week Range: $1.36 to $7.05
• Volume: 1.58 million shs
• Average Volume: 640,717 shs
• Market Capitalization: $3.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

XORTX Therapeutics Stock Analysis - MarketRank™

XORTX Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

XORTX Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

XORTX Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of XORTX Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XORTX Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XORTX Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.64% of the float of XORTX Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

XORTX Therapeutics has a short interest ratio ("days to cover") of 0.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in XORTX Therapeutics has recently decreased by 19.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XORTX Therapeutics does not currently pay a dividend.

Dividend Growth

XORTX Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.02

News Sentiment

XORTX Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for XORTX Therapeutics this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for XRTX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

4 people have added XORTX Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XORTX Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of XORTX Therapeutics is held by insiders.

Percentage Held by Institutions

0.23% of the stock of XORTX Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/15/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:XRTX
• CIK: 1284823
• Web: www.xyratex.com
• Phone: +44-23-92496000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -137.85%
• Return on Assets: -108.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.58
• Quick Ratio: 3.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 1,820,000
• Free Float: 1,692,000
• Market Cap: $3.17 million
• Optionable: Not Optionable
• Beta: 0.78